Our data suggest that ARL6IP5 is a tumor-suppressor that may be involved in the development, progression, and cisplatin-resistance of OC, in support of its clinical significance; therefore, ARL6IP5 expression may be used as a prognostic biomarker for OC. This evidence concerns the gene ARL6IP5 and neoplasm.